Time for Accountability

Nazis face justice

Canada’s youth mental health crisis is no longer just a medical story—it is a legal and institutional failure with mounting liability risks. High-risk antipsychotics like olanzapine (Zyprexa) are prescribed off-label to children and adolescents at unprecedented rates, often by family physicians without specialist oversight, mandatory monitoring, or full transparency on industry influences.

Quebec, home to a thriving pharmaceutical sector, shows some of the highest rates in the country, tripling from ~1.6% to nearly 4.9% over two decades in public plan data. Nationally, CIHI reports a 13% rise in youth antipsychotic dispensing (2018–2019 to 2023–2024) in tracked provinces, but Quebec’s elevated baseline and economic dependence on pharma giants make it ground zero for scrutiny.

This pattern—off-label use for behavioral issues, aggression, anxiety, or mood symptoms (including comorbidities in gender dysphoria cases)—exposes vulnerable youth to severe, lifelong risks: rapid metabolic damage, diabetes, obesity, hormonal disruptions, and sedation. SSRIs add black-box suicidality warnings for young people. Yet Canadian law provides no mandatory safeguards: no public named disclosure of pharma payments to physicians, no enforced specialist consult for high-risk youth psychotropics, no standardized metabolic monitoring protocols with legal teeth.

The result? A system where medications intended to stabilize can become part of unmanaged risk, especially when layered with specialist shortages, rural access barriers, fragmented care, and opaque industry ties.

Off-Label Prescribing: Legal but Liable

Off-label use is legally permitted—it falls under provincial medical regulation—but it carries heightened liability when risks are foreseeable and safeguards absent. In minors, physicians owe an elevated duty of care: informed consent must explicitly cover black-box warnings and metabolic monitoring needs. Failure to explore non-drug options first, or to monitor weight/glucose/lipids, can cross into negligence.

Provincial Colleges of Physicians (e.g., Collège des médecins du Québec) can discipline for substandard care or undisclosed conflicts (per CMA ethics code), but enforcement is reactive. No federal or provincial statute mandates specialist referral for off-label atypicals in youth, unlike some guidelines that recommend it. Voluntary pharma payment disclosures (Innovative Medicines Canada) remain anonymous and incomplete—Canada lags far behind the U.S. Open Payments database or stalled provincial bills like Ontario’s Health Sector Payment Transparency Act.

When harm occurs—e.g., rapid 30+ lb weight gain leading to diabetes, or unmanaged agitation in complex cases—potential civil suits (malpractice), College complaints (misconduct), or even Charter challenges (s.7 security of person via inadequate safe care; s.15 equality for youth with complex needs) become realistic pathways.

Tragedies as Warning Signs

Cases like the 2026 Tumbler Ridge school attack—where the shooter (18, transgender woman with documented MDD, autism, OCD, HRT access struggles, repeated mental health apprehensions) navigated a patchwork of hospitalizations and interventions—expose systemic fragility. While no proven causation exists, such events raise questions: Were psychiatric meds (SSRIs/atypicals for co-morbid symptoms) adequately monitored? Did access barriers or poor coordination compound risks? Public safety demands answers, not speculation.

History’s Liability Lessons

Canada has paid dearly for delayed oversight:

Thalidomide (approved 1961, withdrawn late 1962): Over 100 confirmed malformations; decades of advocacy for compensation. Government/industry faced liability for ignoring warnings.

Vioxx, Fen-Phen, DES, OxyContin: Billions in settlements after downplayed risks and delayed action.

The pattern: Systems protect economic interests until harm accumulates, then react with apologies and cheques. Youth antipsychotic overreach could follow—metabolic class actions, College investigations, or inquiries if tragedies link to unmanaged prescribing.

Reforms: From Reactive to Proactive Law

Protecting Quebec’s pharma jobs and innovation does not require sacrificing youth safeguards. Quebec should lead:

Mandatory named disclosure registry for all pharma payments to physicians—searchable, public, modeled on U.S. standards.
Legislated specialist consult for off-label antipsychotics in minors, with documented justification.
Enforceable monitoring protocols—baseline/ongoing metabolic labs, enforceable via Colleges/Health Canada.
Investment in non-pharma youth supports—therapy, school programs, rural telepsychiatry—as Charter-aligned rights to evidence-based care.
Independent reviews of high-risk prescribing patterns where economic incentives intersect with adverse outcomes.

These are not anti-industry—they are pro-safety, pro-accountability. Quebec’s pharma backbone can thrive alongside transparent, cautious prescribing.

Kicker

The next reckoning won’t be a surprise commission or retroactive cheque. It will be preventable harm turned irreversible—metabolic scars, lost futures, or public safety failures from unmanaged risks. Canadian law must evolve from apology to prevention. Quebec has the economic clout to set the standard—will it choose protection over inertia?

This piece complements another article: medical/economic focus there, legal/liability/reform here. The one above obviously concerns public safety through systemic accountability.

Read the companion article here: McColl Magazine Daily: Quebec’s Pharma Power vs. North America’s Youth